2021
A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus
Dittus C, Grover N, Sethi T, Cohen J, Voloschin A, Rabadey J, Tan X, Beaven A, Park S. A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus. Blood 2021, 138: 1457. DOI: 10.1182/blood-2021-145133.Peer-Reviewed Original ResearchPrimary CNS lymphomaWhole-brain radiation therapyHD-MTXNon-Hodgkin lymphomaReal-world survivalPCNSL groupMedian PFSAntiretroviral therapyWorse OSPerformance statusEntire cohortAstra ZenecaDiffuse large B-cell lymphoma histologyExact testPrimary central nervous system lymphomaAutologous stem cell transplantExtranodal non-Hodgkin lymphomaCentral nervous system lymphomaLactose dehydrogenaseSignificant differencesCentral nervous system tumorsSeattle GeneticsAdvisory CommitteeDeep structure involvementHD-MTX treatmentNo Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis
Allen P, Goyal S, Greenwell I, Scribner J, Rangarajan S, Mehta A, O'Leary C, Niyogusaba T, Huen A, Switchenko J, Tarabadkar E, Ayers A, Krishnasamy S, Porcu P, Sethi T, Iyer S, Lechowicz M. No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis. Blood 2021, 138: 2441. DOI: 10.1182/blood-2021-151911.Peer-Reviewed Original ResearchMF/SSWhite blood cell countB patientsNB patientsMedian survivalSézary syndromeInferior survivalSystemic therapyMycosis fungoidesBlack patientsInsurance statusSeattle GeneticsExact testMultivariate Cox proportional hazards modelT-cell receptor clonalityHigh rateCox proportional hazards modelAdvisory CommitteeHigher nodal stageLarge registry studyHigh-risk featuresMulticenter retrospective analysisNumber of comorbiditiesYear of diagnosisKaplan-Meier curves
2019
Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Epperla N, Costa L, Vaughn J, Hanel W, Raya S, Cashen A, Sarmad R, Badar T, Hamadani M, Liu Y, Barta S, Caimi P, Sethi T, Reddy N, Burkart M, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Ballard H, Svoboda J, Emery L, Lansigan F, Glenn M, Churnetski M, Cohen J, Sorge C, Xavier A. Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. Blood 2019, 134: 1554. DOI: 10.1182/blood-2019-129199.Peer-Reviewed Original ResearchPR/stable diseasePrimary treatment failureClassical Hodgkin lymphomaAnthracycline-containing chemotherapy regimensOutcomes of patientsHigh-dose chemotherapyStable diseaseOverall survivalER cohortComplete remissionSeattle GeneticsSpeakers bureauPP cohortSalvage therapyChemotherapy regimensProgressive diseasePartial responseTreatment failureHodgkin's lymphomaNew agentsAdvanced-stage classical Hodgkin lymphomaFive-year overall survivalRelapsed classical Hodgkin lymphomaAutologous hematopoietic cell transplantationRefractory classical Hodgkin lymphoma